1-3 of 3
Kelesitse Phiri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Francesca Palandri, Venediktos Kapetanakis, Balazs Dobi, Filippo Branzanti, Catherine Ellis, Nick Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Melania Biasi, Shiyuan Zhang, Dwaipayan Patnaik
Journal: Blood
Blood (2024) 144 (Supplement 1): 3187.
https://doi.org/10.1182/blood-2024-205973
Published: 2024
Journal Articles

Anemia and Transfusion Dependency Are Important Prognostic Factors for Overall Survival in Patients with Myelofibrosis: Results of a Real-World Analysis of Medicare Patients

Aaron T. Gerds, Ruben A. Mesa, Joseph Tkacz, Laura Moore-Schiltz, Jill Schinkel, Kelesitse Phiri, Tom Liu, Boris Gorsh
Journal: Blood
Blood (2023) 142 (Supplement 1): 6418.
https://doi.org/10.1182/blood-2023-178012
Published: 2023
Journal Articles

Retrospective Real-World Analysis of Baseline Characteristics and Posttreatment Hematologic Outcomes in Patients with Myelofibrosis Receiving Ruxolitinib

Andrew T. Kuykendall, Mirko Fillbrunn, Tom Liu, Adina Zhang, Ryan Simpson, Kelesitse Phiri, Gautam Sajeev, James Signorovitch
Journal: Blood
Blood (2023) 142 (Supplement 1): 6399.
https://doi.org/10.1182/blood-2023-181137
Published: 2023